Upcoming earnings releases in Asia, as well as the rest of the world, also added to the wait-and-see mood. On Wall Street, ...

U.S. stock indexes dipped as Eli Lilly and chip companies fell, overshadowing Alphabet's rise. AMD's forecast disappointed, while Eli Lilly faced product concerns. Bond yields rose amid economic ...

The S&P 500 slipped 0.3 percent after drifting between small gains and losses several times, though it's still near its ...

Eli Lilly ( LLY) is planning to advertise its blockbuster weight loss drug, Zepbound, for the first time next month. Despite investor and industry recognition of the branded GLP-1 drug, "unaided ...

Eli Lilly’s stock heads for biggest selloff in more than three years after sales of anti-obesity drugs Mounjaro and Zepbound ...

Eli Lilly shares slid after the drugmaker reported disappointing quarterly results, with sales of its popular diabetes and anti-obesity drugs lower than expected. Lilly said inventory decreases by ...

U.S. stock indexes gave up an early gain and ended slightly lower following a mixed set of profit reports from giants like ...

Skyrocketing demand for weight loss and diabetes drugs has forced Eli Lilly and Novo Nordisk, to invest billions to increase ...

All doses of the two drugs are now listed as available in the U.S., per an FDA database, although the company cautioned ...

Eli Lilly' s blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the ...

LLY’s slashed revenue and earnings guidance for 2024 were a surprise, especially given substantial raises to its outlook ...